RT Journal Article
SR Electronic
T1 Identification of acute exacerbations of chronic obstructive pulmonary disease using simple patient-reported symptoms and cough feature analysis: A diagnostic agreement study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.13.20247486
DO 10.1101/2020.12.13.20247486
A1 Claxton, Scott
A1 Porter, Paul
A1 Brisbane, Joanna
A1 Bear, Natasha
A1 Wood, Javan
A1 Peltonen, Vesa
A1 Della, Phillip
A1 Smith, Claire
A1 Abeyratne, Udantha
YR 2020
UL http://medrxiv.org/content/early/2020/12/14/2020.12.13.20247486.abstract
AB Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) are commonly encountered in the primary care setting, though accurate and timely diagnosis is problematic. Using technology like that employed in speech recognition technology, we developed a smartphone-based algorithm for rapid and accurate diagnosis of AECOPD. The algorithm incorporates patient-reported features (age, fever, new cough), audio data from five coughs and can be deployed by novice users. We compared the accuracy of the algorithm to expert clinical assessment. In patients with known COPD, the algorithm correctly identified the presence of AECOPD in 82.6% (95% CI: 72.9-89.9%) of subjects (n=86). The absence of AECOPD was correctly identified in 91.0% (95% CI: 82.4-96.3%) of individuals (n=78). Diagnostic agreement was maintained in milder cases of AECOPD (PPA: 79.2%, 95% CI: 68.0-87.8%), who typically comprise the cohort presenting to primary care. The algorithm may aid early identification of AECOPD and be incorporated in patient self-management plans.Competing Interest StatementPP, SC and UA are scientific advisors of ResApp Health (RAP). PP and UA are shareholders in RAP. UA was RAP's Chief Scientist. RAP is an Australian publicly listed company commercializing the technology under license from the University of Queensland, where UA is employed. UA is a named inventor of the UQ technology. VS and JW are employees of ResApp Health. NB, JB, CS and PD declare no competing interests.Clinical TrialACTRN12618001521213Funding StatementResApp Health provided funding to support the Breathe Easy Program at JHC and UQ. Joondalup Health Campus provided office space, IT services and consumables in kind.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all participants and ethical approval was given for the study by the Ramsay Health Care WA|SA Human Research Ethics Committee (REF: 1501).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe underlying codes are the property of ResApp Health and are not available. The datasets supporting the conclusion of this article are available on reasonable request from PP. The cough recordings are not available but will be uploaded as an educational tool in the future.